Medpace (NASDAQ:MEDP – Get Free Report) and Personalis (NASDAQ:PSNL – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Medpace and Personalis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medpace | $2.53 billion | 6.79 | $451.12 million | $17.06 | 36.10 |
| Personalis | $69.65 million | 24.54 | -$81.27 million | ($1.09) | -14.97 |
Risk & Volatility
Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Personalis has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Medpace and Personalis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medpace | 0 | 9 | 3 | 0 | 2.25 |
| Personalis | 1 | 5 | 4 | 0 | 2.30 |
Medpace presently has a consensus target price of $595.20, suggesting a potential downside of 3.37%. Personalis has a consensus target price of $14.54, suggesting a potential downside of 10.93%. Given Medpace’s higher probable upside, research analysts plainly believe Medpace is more favorable than Personalis.
Insider and Institutional Ownership
78.0% of Medpace shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Medpace and Personalis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medpace | 17.67% | 110.15% | 24.84% |
| Personalis | -153.84% | -46.47% | -35.30% |
Summary
Medpace beats Personalis on 10 of the 14 factors compared between the two stocks.
About Medpace
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
About Personalis
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
